Stock A.P. PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News A.P. Pharma, Inc. Other OTC

Equities

US00202J2033

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for A.P. Pharma, Inc.
07-02 Heron Reports Acceptance of Prior Approval Supplement Application for Zynrelef Vial Access Needle MT
07-02 Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Heron Reports Acceptance of Prior Approval Supplement Application for Zynrelef Vial Access Needle
MT
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
PR
Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle
CI
Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to S&P Biotechnology Select Industry Index
CI
Connect Biopharma Names New Chief Executive, Chair
MT
Heron Therapeutics Submits Prior Approval Supplement to the FDA for Zynrelef Vial Access Needle
MT
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
PR
Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
CI
Heron Therapeutics : Investor Day Presentation
PU
Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day
Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
Heron Therapeutics: Q1 Earnings Snapshot
AQ
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024
CI
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
PR
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
PR
Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target
MT
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
PR
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
PR
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HRTX Stock
  4. Stock
  5. News A.P. Pharma, Inc.